ISBN 10: 1484907787 / ISBN 13: 9781484907788
Usato / Quantità: 0
Copie del libro da altre librerie
Mostra tutte le  copie di questo libro

Libro

Purtroppo questa copia non è più disponibile. Di seguito ti proponiamo una lista di copie simili.

Descrizione:

Brand New, Unread Copy in Perfect Condition. A+ Customer Service! Summary: Probiotics (literally, "for life") are bacteria or yeasts considered to confer a health benefit on the host organism. This review addresses the safety of probiotics used in research to reduce the risk of, prevent, or treat disease. The review objective was to catalog what is known about the safety of interventions containing organisms from six different genera used as probiotic agents (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus), alone or in combination, used to reduce the risk of, prevent, or treat disease in research studies. This evidence report has a broad scope and was not restricted to specific interventions, specific patient groups, or specific clinical outcomes. The large number of included studies allowed unique analyses to explore adverse events reported to date in research on probiotics. The definition of what is a probiotic has evolved as the sciences of microbiology, medicine, and the manufacturing industries have matured. According to one definition offered by an expert committee convened by the Food and Agriculture Organization of the United Nations and the World Health Organization, probiotic organisms are live microorganisms that when administered in adequate amounts confer a health benefit on the host (FAO/WHO, 2001). This definition explicitly restricts what can be considered a probiotic to live organisms. Other definitions do not emphasize the viability of the microorganisms and would include heat-killed preparations (e.g., Salminen, Ouwehand, Benno, & Lee, 1999). Defining probiotics is challenging because of the limits in our understanding of how organisms benefit the human host, the apparent variation in what may constitute a beneficial balance for digestion and other physiological processes, the effects of probiotic organisms on the normal gut environment, and our limited understanding of the gut ecosystem (Schmid, 2006). The review set out to answer a number of research questions posed by the sponsors of the evidence review. Key questions include:Key Question 1. What is the evidence that the active and lyophilized forms of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus) as single ingredients or in combination with other probiotics or prebiotics in all delivery vehicles (and formulations) when used to cure, treat, mitigate, or prevent a disease or reduce disease risk are safe in the short term? In the long term? Key Question 2. What are characteristics and associations of the reported harms in Question 1? Key Question 3. What is the evidence that harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus differ by product and delivery characteristics? Key Question 4. How do the harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus vary based on dose; (b) timing; (c) mode of administration; (d) age, gender, ethnicity, disease or immunologic status; (e) relationship to efficacy? Key Question 5. How often does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus lead to hospital admission or lengthened hospitalization? Key Question 6. How does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus relate to use of concomitant antibiotics, confounding diet therapies, corticosteroid use, immune suppressants, or other potential confounders?. Codice inventario libreria

Su questo libro:

Book ratings provided by GoodReads):
0 valutazione media
(0 valutazioni)

Riassunto: Probiotics (literally, ?for life?) are bacteria or yeasts considered to confer a health benefit on the host organism. This review addresses the safety of probiotics used in research to reduce the risk of, prevent, or treat disease. The review objective was to catalog what is known about the safety of interventions containing organisms from six different genera used as probiotic agents (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus), alone or in combination, used to reduce the risk of, prevent, or treat disease in research studies. This evidence report has a broad scope and was not restricted to specific interventions, specific patient groups, or specific clinical outcomes. The large number of included studies allowed unique analyses to explore adverse events reported to date in research on probiotics. The definition of what is a probiotic has evolved as the sciences of microbiology, medicine, and the manufacturing industries have matured. According to one definition offered by an expert committee convened by the Food and Agriculture Organization of the United Nations and the World Health Organization, probiotic organisms are live microorganisms that when administered in adequate amounts confer a health benefit on the host (FAO/WHO, 2001). This definition explicitly restricts what can be considered a probiotic to live organisms. Other definitions do not emphasize the viability of the microorganisms and would include heat-killed preparations (e.g., Salminen, Ouwehand, Benno, & Lee, 1999). Defining probiotics is challenging because of the limits in our understanding of how organisms benefit the human host, the apparent variation in what may constitute a beneficial balance for digestion and other physiological processes, the effects of probiotic organisms on the normal gut environment, and our limited understanding of the gut ecosystem (Schmid, 2006). The review set out to answer a number of research questions posed by the sponsors of the evidence review. Key questions include:Key Question 1. What is the evidence that the active and lyophilized forms of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus) as single ingredients or in combination with other probiotics or prebiotics in all delivery vehicles (and formulations) when used to cure, treat, mitigate, or prevent a disease or reduce disease risk are safe in the short term? In the long term? Key Question 2. What are characteristics and associations of the reported harms in Question 1? Key Question 3. What is the evidence that harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus differ by product and delivery characteristics? Key Question 4. How do the harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus vary based on dose; (b) timing; (c) mode of administration; (d) age, gender, ethnicity, disease or immunologic status; (e) relationship to efficacy? Key Question 5. How often does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus lead to hospital admission or lengthened hospitalization? Key Question 6. How does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus relate to use of concomitant antibiotics, confounding diet therapies, corticosteroid use, immune suppressants, or other potential confounders?

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Dati bibliografici

Condizione libro: New

I migliori risultati di ricerca su AbeBooks

1.

Human Services, U. S. Department of Heal
ISBN 10: 1484907787 ISBN 13: 9781484907788
Usato Quantità: 1
Da
Books2Anywhere
(Fairford, GLOS, Regno Unito)
Valutazione libreria
[?]

Descrizione libro 2013. PAP. Condizione libro: Used - Very Good. Used - Like New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Codice libro della libreria XS-CRL-27285945

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra usato
EUR 4,09
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 10,39
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

2.

ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi Quantità: > 20
Print on Demand
Da
BWB
(Valley Stream, NY, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Condizione libro: New. This item is Print on Demand - Depending on your location, this item may ship from the US or UK. Codice libro della libreria POD_9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 47,63
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

3.

Human Services, U. S. Department of Heal
ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi Quantità: > 20
Print on Demand
Da
PBShop
(Wood Dale, IL, U.S.A.)
Valutazione libreria
[?]

Descrizione libro 2013. PAP. Condizione libro: New. New Book. Shipped from US within 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Codice libro della libreria I2-9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 45,87
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,69
In U.S.A.
Destinazione, tempi e costi

4.

Human Services, U. S. Department of Heal
ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi Quantità: > 20
Print on Demand
Da
Books2Anywhere
(Fairford, GLOS, Regno Unito)
Valutazione libreria
[?]

Descrizione libro 2013. PAP. Condizione libro: New. New Book. Delivered from our UK warehouse in 3 to 5 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Codice libro della libreria IQ-9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 47,00
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 10,39
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

5.

Human Services, U. S. Department of Health and; and Quality, Agency for Healthcare Research
Editore: CreateSpace Independent Publishing Platform
ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi PAPERBACK Quantità: > 20
Da
Russell Books
(Victoria, BC, Canada)
Valutazione libreria
[?]

Descrizione libro CreateSpace Independent Publishing Platform. PAPERBACK. Condizione libro: New. 1484907787 Special order direct from the distributor. Codice libro della libreria ING9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 48,21
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 6,47
Da: Canada a: U.S.A.
Destinazione, tempi e costi

6.

U. S. Department of Health and Human Services
Editore: Createspace
ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi Paperback Quantità: 20
Print on Demand
Da
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Createspace. Paperback. Condizione libro: New. This item is printed on demand. Paperback. 646 pages. Dimensions: 9.2in. x 7.5in. x 1.5in.Probiotics (literally, for life) are bacteria or yeasts considered to confer a health benefit on the host organism. This review addresses the safety of probiotics used in research to reduce the risk of, prevent, or treat disease. The review objective was to catalog what is known about the safety of interventions containing organisms from six different genera used as probiotic agents (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus), alone or in combination, used to reduce the risk of, prevent, or treat disease in research studies. This evidence report has a broad scope and was not restricted to specific interventions, specific patient groups, or specific clinical outcomes. The large number of included studies allowed unique analyses to explore adverse events reported to date in research on probiotics. The definition of what is a probiotic has evolved as the sciences of microbiology, medicine, and the manufacturing industries have matured. According to one definition offered by an expert committee convened by the Food and Agriculture Organization of the United Nations and the World Health Organization, probiotic organisms are live microorganisms that when administered in adequate amounts confer a health benefit on the host (FAOWHO, 2001). This definition explicitly restricts what can be considered a probiotic to live organisms. Other definitions do not emphasize the viability of the microorganisms and would include heat-killed preparations (e. g. , Salminen, Ouwehand, Benno, and Lee, 1999). Defining probiotics is challenging because of the limits in our understanding of how organisms benefit the human host, the apparent variation in what may constitute a beneficial balance for digestion and other physiological processes, the effects of probiotic organisms on the normal gut environment, and our limited understanding of the gut ecosystem (Schmid, 2006). The review set out to answer a number of research questions posed by the sponsors of the evidence review. Key questions include: Key Question 1. What is the evidence that the active and lyophilized forms of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus) as single ingredients or in combination with other probiotics or prebiotics in all delivery vehicles (and formulations) when used to cure, treat, mitigate, or prevent a disease or reduce disease risk are safe in the short term In the long term Key Question 2. What are characteristics and associations of the reported harms in Question 1 Key Question 3. What is the evidence that harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus differ by product and delivery characteristics Key Question 4. How do the harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus vary based on dose; (b) timing; (c) mode of administration; (d) age, gender, ethnicity, disease or immunologic status; (e) relationship to efficacy Key Question 5. How often does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus lead to hospital admission or lengthened hospitalization Key Question 6. How does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus relate to use of concomitant antibiotics, confounding diet therapies, corticosteroid use, immune suppressants, or other potential confounders This item ships from La Vergne,TN. Paperback. Codice libro della libreria 9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 55,61
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,65
In U.S.A.
Destinazione, tempi e costi

7.

U S Department of Heal Human Services, Agency for Healthcare Resea And Quality
Editore: Createspace, United States (2013)
ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi Paperback Quantità: 10
Print on Demand
Da
The Book Depository US
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Createspace, United States, 2013. Paperback. Condizione libro: New. 282 x 218 mm. Language: English . Brand New Book ***** Print on Demand *****. Probiotics (literally, for life ) are bacteria or yeasts considered to confer a health benefit on the host organism. This review addresses the safety of probiotics used in research to reduce the risk of, prevent, or treat disease. The review objective was to catalog what is known about the safety of interventions containing organisms from six different genera used as probiotic agents (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus), alone or in combination, used to reduce the risk of, prevent, or treat disease in research studies. This evidence report has a broad scope and was not restricted to specific interventions, specific patient groups, or specific clinical outcomes. The large number of included studies allowed unique analyses to explore adverse events reported to date in research on probiotics. The definition of what is a probiotic has evolved as the sciences of microbiology, medicine, and the manufacturing industries have matured. According to one definition offered by an expert committee convened by the Food and Agriculture Organization of the United Nations and the World Health Organization, probiotic organisms are live microorganisms that when administered in adequate amounts confer a health benefit on the host (FAO/WHO, 2001). This definition explicitly restricts what can be considered a probiotic to live organisms. Other definitions do not emphasize the viability of the microorganisms and would include heat-killed preparations (e.g., Salminen, Ouwehand, Benno, Lee, 1999). Defining probiotics is challenging because of the limits in our understanding of how organisms benefit the human host, the apparent variation in what may constitute a beneficial balance for digestion and other physiological processes, the effects of probiotic organisms on the normal gut environment, and our limited understanding of the gut ecosystem (Schmid, 2006). The review set out to answer a number of research questions posed by the sponsors of the evidence review. Key questions include: Key Question 1. What is the evidence that the active and lyophilized forms of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus) as single ingredients or in combination with other probiotics or prebiotics in all delivery vehicles (and formulations) when used to cure, treat, mitigate, or prevent a disease or reduce disease risk are safe in the short term? In the long term? Key Question 2. What are characteristics and associations of the reported harms in Question 1? Key Question 3. What is the evidence that harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus differ by product and delivery characteristics? Key Question 4. How do the harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus vary based on dose; (b) timing; (c) mode of administration; (d) age, gender, ethnicity, disease or immunologic status; (e) relationship to efficacy? Key Question 5. How often does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus lead to hospital admission or lengthened hospitalization? Key Question 6. How does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus relate to use of concomitant antibiotics, confounding diet therapies, corticosteroid use, immune suppressants, or other potential confounders?. Codice libro della libreria APC9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 65,36
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

8.

U S Department of Heal Human Services, Agency for Healthcare Resea And Quality
Editore: Createspace, United States (2013)
ISBN 10: 1484907787 ISBN 13: 9781484907788
Nuovi Paperback Quantità: 10
Print on Demand
Da
The Book Depository
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Createspace, United States, 2013. Paperback. Condizione libro: New. 282 x 218 mm. Language: English . Brand New Book ***** Print on Demand *****.Probiotics (literally, for life ) are bacteria or yeasts considered to confer a health benefit on the host organism. This review addresses the safety of probiotics used in research to reduce the risk of, prevent, or treat disease. The review objective was to catalog what is known about the safety of interventions containing organisms from six different genera used as probiotic agents (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus), alone or in combination, used to reduce the risk of, prevent, or treat disease in research studies. This evidence report has a broad scope and was not restricted to specific interventions, specific patient groups, or specific clinical outcomes. The large number of included studies allowed unique analyses to explore adverse events reported to date in research on probiotics. The definition of what is a probiotic has evolved as the sciences of microbiology, medicine, and the manufacturing industries have matured. According to one definition offered by an expert committee convened by the Food and Agriculture Organization of the United Nations and the World Health Organization, probiotic organisms are live microorganisms that when administered in adequate amounts confer a health benefit on the host (FAO/WHO, 2001). This definition explicitly restricts what can be considered a probiotic to live organisms. Other definitions do not emphasize the viability of the microorganisms and would include heat-killed preparations (e.g., Salminen, Ouwehand, Benno, Lee, 1999). Defining probiotics is challenging because of the limits in our understanding of how organisms benefit the human host, the apparent variation in what may constitute a beneficial balance for digestion and other physiological processes, the effects of probiotic organisms on the normal gut environment, and our limited understanding of the gut ecosystem (Schmid, 2006). The review set out to answer a number of research questions posed by the sponsors of the evidence review. Key questions include: Key Question 1. What is the evidence that the active and lyophilized forms of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus) as single ingredients or in combination with other probiotics or prebiotics in all delivery vehicles (and formulations) when used to cure, treat, mitigate, or prevent a disease or reduce disease risk are safe in the short term? In the long term? Key Question 2. What are characteristics and associations of the reported harms in Question 1? Key Question 3. What is the evidence that harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus differ by product and delivery characteristics? Key Question 4. How do the harms of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus vary based on dose; (b) timing; (c) mode of administration; (d) age, gender, ethnicity, disease or immunologic status; (e) relationship to efficacy? Key Question 5. How often does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus lead to hospital admission or lengthened hospitalization? Key Question 6. How does harm associated with Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus relate to use of concomitant antibiotics, confounding diet therapies, corticosteroid use, immune suppressants, or other potential confounders?. Codice libro della libreria APC9781484907788

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 65,82
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi